NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis $2.84 +0.07 (+2.53%) Closing price 04:00 PM EasternExtended Trading$2.82 -0.02 (-0.70%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OncoCyte Stock (NASDAQ:OCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OncoCyte alerts:Sign Up Key Stats Today's Range$2.63▼$2.9150-Day Range$2.01▼$4.1752-Week Range$1.92▼$4.75Volume38,208 shsAverage Volume66,453 shsMarket Capitalization$81.22 millionP/E RatioN/ADividend YieldN/APrice Target$4.56Consensus RatingModerate Buy Company OverviewOncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More… Remove Ads OncoCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreOCX MarketRank™: OncoCyte scored higher than 44% of companies evaluated by MarketBeat, and ranked 542nd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days.Read more about OncoCyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoCyte is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoCyte is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OncoCyte's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.53% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in OncoCyte has recently increased by 22.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.53% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in OncoCyte has recently increased by 22.36%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.59 News SentimentOncoCyte has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for OncoCyte this week, compared to 2 articles on an average week.Search Interest7 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,430,510.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.58% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OncoCyte's insider trading history. Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Stock News HeadlinesOncoCyte Co. (NASDAQ:OCX) Short Interest UpdateApril 4 at 1:57 AM | americanbankingnews.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 7, 2025 | Porter & Company (Ad)OncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comSee More Headlines OCX Stock Analysis - Frequently Asked Questions How have OCX shares performed this year? OncoCyte's stock was trading at $2.38 on January 1st, 2025. Since then, OCX stock has increased by 19.3% and is now trading at $2.84. View the best growth stocks for 2025 here. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings data on Monday, March, 24th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.88. The business earned $1.49 million during the quarter, compared to the consensus estimate of $0.16 million. OncoCyte had a negative trailing twelve-month return on equity of 269.32% and a negative net margin of 6,122.29%. When did OncoCyte's stock split? Shares of OncoCyte reverse split on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F). Company Calendar Last Earnings3/24/2025Today4/07/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCX CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.56 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+66.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,780,000.00 Net Margins-6,122.29% Pretax Margin-6,085.19% Return on Equity-269.32% Return on Assets-59.71% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.50 Sales & Book Value Annual Sales$1.88 million Price / Sales41.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book1.10Miscellaneous Outstanding Shares28,599,000Free Float17,177,000Market Cap$78.19 million OptionableNo Data Beta0.97 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:OCX) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.